Afrigen

15/07/2026

🔹 🔹 Disease is no longer the biggest obstacle facing modern medicine.🔹 🔹

Access is. The question is: "Can Science cure disease without creating inequality?"

In this episode of The Enhanced Pod, Professor Michael Pepper explains why cures for cancer, gene editing and personalised medicine are advancing faster than most people realise—but also why millions of people may never benefit from them.

We investigate:

🔬 Why African genomes remain dramatically underrepresented in medical research

🔬 Whether AI can replace clinical trials

🔬 The promise—and dangers—of CRISPR gene editing

🔬 Why curing HIV is scientifically possible but economically difficult

🔬 How misinformation has become one of science's greatest threats

🔬 The ethical line between treating disease and enhancing humans

This isn't simply a conversation about medicine.

🔹 It's about who gets included in the future.🔹

https://www.youtube.com/watch?v=xda8woPndPs

03/07/2026

🔹 Ramaphosa vows South African support for DRC as Ebola outbreak continues 🔹

"... Three immediate priorities

Cyril Ramaphosa identified three immediate priorities for the Ebola response. First, he said it was critical to accelerate conversion of financial pledges into practical support, including funding, technical assistance and delivery of medical countermeasures to affected areas.

Second, he called for a ceasefire to enable humanitarian access, so healthcare workers, aid agencies and medical supplies could reach communities safely, and urged communities to protect frontline responders from intimidation, stigma and violence. He said:

“Healthcare workers must never face fear, stigma or violence while serving our people.”

Third, Ramaphosa reaffirmed South Africa’s commitment to strengthening local vaccine manufacturing, confirming that South African biotechnology company Afrigen Biologics (Pty) Ltd continues to support efforts to develop a vaccine targeting the Bundibugyo strain responsible for the current outbreak..."

Read the whole article ⬇️



https://lnkd.in/dTx4hnkM

03/07/2026

🔹 Kenya's Vaccine Manufacturing Push Signals a New Chapter for Africa's Health Sovereignty 🔹

"Earlier this year, Kenya joined the World Health Organization (WHO) and Medicines Patent Pool (MPP) mRNA Technology Transfer Programme, becoming one of six African countries selected to participate in the initiative.

The programme enables participating countries to acquire the technical knowledge required to manufacture hashtag vaccines for routine immunisation, malaria, tuberculosis and future pandemic preparedness."

https://lnkd.in/d6N34VQf

03/06/2026

🔬 The scientific community is facing rapid change, making it more important than ever to understand the evolving landscape of research careers worldwide.

🔹 We encourage scientists, researchers, academics, and research professionals across our network to participate in this important global survey highlighted by Nature. Your insights will help build a clearer picture of emerging trends, challenges, and opportunities in scientific careers across different regions and disciplines.

🔬The findings will contribute to a stronger evidence base for protecting, supporting, and promoting careers in science—ensuring that research remains an attractive, sustainable, and impactful profession for future generations.

Every voice matters. Please take a few moments to participate and share with your colleagues.

📘 Read more and access the survey here:

https://www.nature.com/articles/d41586-026-01589-3

27/05/2026

🔹 Afrigen's SAHPRA GMP Accreditation 🔹

📆 27 May 2026

Stronger health systems, greater collaboration, and innovation that creates lasting impact. 💪

27/05/2026

🔹 Progress in global health is built through partnerships, innovation, and a shared commitment to improving lives. Watch the video below for insights on shaping a stronger and more resilient future. 🔹

🔗 📲 https://lnkd.in/dxTFpzM2

Afrigen Biologics (Pty) Ltd World Health Organization

27/05/2026

🔹 Afrigen Biologics (Pty) Ltd Biologics has secured GMP certification from for its facility in Cape Town — a major milestone for South African biotechnology and African vaccine manufacturing. 🔹

This means the facility now meets internationally recognised manufacturing standards and is authorised to manufacture investigational biological products for Phase I and II clinical trials.

Afrigen plays a central role in the World Health Organization- and Medicines Patent Pool-co-led mRNA Technology Transfer Programme, helping build sustainable regional manufacturing capacity, strengthen health security and support pandemic preparedness.

Read more here ⬇️

https://lnkd.in/ddvF_eKY

27/05/2026

🎉 Join us LIVE at 16:00 as Afrigen marks a major milestone for African health innovation!

Afrigen is today GMP-certified by SAHPRA — proving that Africa can build world-class mRNA manufacturing capacity. 🌍🧬

From concept to a fully operational facility in just four years, Afrigen is helping shape a more resilient and equitable future for global vaccine access.

🔗 Join the webinar live: https://us06web.zoom.us/webinar/register/WN_K6MkMnSRSBW1akP3mipYkA

From technology development and transfer to good manufacturing production — delivering on the promise of local innovation and production for equitable access.

16/05/2026

🔹 Kenya unveils major push for local vaccine manufacturing as French Minister visits BioVax Institute 🔹

The next phase will focus on installing and validating fill-and-finish equipment, strengthening quality control systems, building specialized workforce capacity, and preparing for compliant .

🔹 mRNA Technology transfer breakthrough 🔹

Speaking during the visit, Principal Secretary for Medical Services Dr. Ouma Oluga noted that officially joined the WHO-Medicines Patent Pool mRNA Technology Transfer Programme in February 2026, positioning the country among a select group of nations building capacity for local vaccine production.



⏬ Read the whole article ⏬

https://www.healthcaremea.com/2026/05/14/egypt-expands-mental-health-services-in-universal-health-insurance-facilities-2/

Afrigen Biologics (Pty) Ltd mRNA Technology Transfer Programme World Health Organization Medicines Patent Pool

15/05/2026

🔹 Bristol scientists developing hantavirus vaccine 'hugely excited' by breakthrough 🔹

EnsiliTech, a University of Bath spin-out now headquartered at Science Creates in St Philips, says its newly-developed antigen targeting hantaan has undergone laboratory testing and is already producing promising results in animals.

The firm has been collaborating with researchers at the University of Texas Medical Branch, alongside Cape Town-based biotechnology company Afrigen Biologics (Pty) Ltd.

Read more ⏬

https://www.bristolpost.co.uk/news/health/bristol-scientists-developing-hantavirus-vaccine-10963727